Welcome to our dedicated page for MARIMED news (Ticker: $MRMD), a resource for investors and traders seeking the latest updates and insights on MARIMED stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MARIMED's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MARIMED's position in the market.
MariMed Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $37.9 million and a positive adjusted EBITDA for the 17th consecutive quarter. The company outperformed its competition in all markets, including Illinois, with significant growth in its wholesale business. MariMed also announced key operational highlights, such as expanding its branded products in Illinois, opening a new dispensary in Maryland, and forming partnerships with Boston music venues. The company's 2024 financial targets include revenue growth of 5-7% and non-GAAP Adjusted EBITDA growth of 0-2%.
MariMed Inc. CEO Jon Levine praises the DEA's decision to move cannabis to Schedule III, highlighting benefits for consumers, patients, communities, investors, and the industry. The reclassification will ease research, boost product innovation, remove tax burdens, and potentially open up financial opportunities.
